Related Experiment Video
Updated: Aug 19, 2026

Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
Application of preclinical data to initiate the modified continual reassessment method for maximum tolerated
1Division of Pharmaceutical Evaluation I, Office of Clinical Pharmacology and Biopharmaceutics (HFD-860), Food and Drug Administration (FDA), Rockville, Maryland, USA.
Abstract:
This study was conducted to evaluate whether the allometric approach can be used to predict maximum tolerated dose (MTD) in humans from animal data. Twenty-five anticancer drugs were taken from the literature and used in this analysis. The results of the study indicate that MTD can be predicted with reasonable accuracy using interspecies scaling. The predicted MTD can then be applied to the modified continual reassessment method retrospectively for the selection of initial and subsequent doses of anticancer drugs in the patient population. This approach can save time and avoid many unnecessary steps to attain MTD in humans if it could be applied prospectively.
More Related Videos
Related Concept Videos
Clinical Trials: Overview
Preclinical Development: Overview
Dosage Regimens: Partial Pharmacokinetic Parameters
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
Therapeutic Drug Monitoring: Drug Analysis Methods
Toxicity Testing in Animals

